Form EFFECT Lyell Immunopharma, Inc.
![SEC EDGAR](../../../Content/images/providers/SC.png)
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: SEC EDGAR
![SEC EDGAR](../../../Content/images/providers/SC.png)
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion TechnologyGlobeNewswire
- Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceGlobeNewswire
- Lyell Immunopharma to Participate in BofA Securities Health Care Conference [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma to Participate in BofA Securities Health Care ConferenceGlobeNewswire
- Lyell Immunopharma, Inc. (NASDAQ: LYEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
LYEL
Analyst Actions
- 5/7/24 - HC Wainwright
LYEL
Sec Filings
- 6/26/24 - Form 8-K
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- LYEL's page on the SEC website